FI20051271L - Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi - Google Patents

Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi Download PDF

Info

Publication number: FI20051271L
Authority: FI; Finland
Prior art keywords: compositions; compounds; gaba receptor; allosteric modulation; allosteric
Prior art date: 1994-02-14

Application number

FI20051271A

Other languages

English (en)

Swedish (sv)

Other versions

FI118687B (fi

Inventor

Ravindra B Upasani

Haiji Xia

Derk Hogenkamp

Original Assignee

Cocensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-14

Filing date

2005-12-09

Publication date

2005-12-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20051271(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-09 Application filed by Cocensys Inc filed Critical Cocensys Inc

2005-12-09 Publication of FI20051271L publication Critical patent/FI20051271L/fi

2008-02-15 Application granted granted Critical

2008-02-15 Publication of FI118687B publication Critical patent/FI118687B/fi

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Dental Preparations (AREA)
Polymerisation Methods In General (AREA)
Adhesives Or Adhesive Processes (AREA)
Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FI20051271A 1994-02-14 2005-12-09 Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi FI118687B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US19691994A	1994-02-14	1994-02-14
US19691994		1994-02-14
US34692794A	1994-11-23	1994-11-23
US34692794		1994-11-23
US9501712		1995-02-14
PCT/US1995/001712 WO1995021617A1 (en)	1994-02-14	1995-02-14	Androstanes and pregnanes for allosteric modulation of gaba receptor

Publications (2)

Publication Number	Publication Date
FI20051271L true FI20051271L (fi)	2005-12-09
FI118687B FI118687B (fi)	2008-02-15

Family

ID=26892391

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FI963174A FI118008B (fi)	1994-02-14	1996-08-13	Androstaanit ja pregnaanit GABA-reseptorin allosteeriseksi moduloimiseksi
FI20051271A FI118687B (fi)	1994-02-14	2005-12-09	Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FI963174A FI118008B (fi)	1994-02-14	1996-08-13	Androstaanit ja pregnaanit GABA-reseptorin allosteeriseksi moduloimiseksi

Country Status (17)

Country	Link
EP (2)	EP1038880B1 (fi)
JP (1)	JP4066272B2 (fi)
KR (1)	KR100338287B1 (fi)
AT (2)	ATE195654T1 (fi)
AU (1)	AU691905B2 (fi)
BR (1)	BR9506779A (fi)
CA (1)	CA2183231A1 (fi)
DE (2)	DE69535623T2 (fi)
DK (2)	DK1038880T3 (fi)
ES (2)	ES2296594T3 (fi)
FI (2)	FI118008B (fi)
GR (1)	GR3034810T3 (fi)
IL (1)	IL112638A (fi)
NO (1)	NO308307B1 (fi)
NZ (1)	NZ282939A (fi)
PT (2)	PT1038880E (fi)
WO (1)	WO1995021617A1 (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6780853B1 (en)	1995-06-06	2004-08-24	Euro-Celtique S.A.	Neuroactive steroids of the androstane and pregnane series
CA2223996A1 (en) *	1995-06-06	1996-12-19	Cocensys, Inc.	Neuroactive steroids of the androstane and pregnane series
US20010051599A1 (en)	1997-05-02	2001-12-13	Michael Z. Kagan	Pregnan-3-ol-20-ones
EP1449846A1 (en) *	1999-04-29	2004-08-25	Euro-Celtique S.A.	3-alpha Hydroxy-3-beta methoxymethyl-21-heterocycle substituted steriods with anaesthetic activity
HUP0201818A3 (en) *	1999-04-29	2004-04-28	Euro Celtique Sa	3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same
JP2001039954A (ja) *	1999-05-24	2001-02-13	Tomono Agrica Co Ltd	ヘテロ環誘導体
EP1228083A2 (en)	1999-09-30	2002-08-07	Hollis-Eden Pharmaceuticals Inc.	Therapeutic treatment of androgen receptor driven conditions
US7078057B2 (en)	1999-12-20	2006-07-18	Kerkhof Nicholas J	Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en)	1999-12-20	2014-07-08	Nicholas J. Kerkhof	Process for producing nanoparticles by spray drying
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
DE602006013622D1 (de) *	2005-06-09	2010-05-27	Euro Celtique Sa	Steroids und anwendungen davon
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
CA2651862A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
JP2010502722A (ja)	2006-09-08	2010-01-28	ブレインセルス，インコーポレイティド	４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
RU2469042C2 (ru) *	2006-09-19	2012-12-10	Зольвай Фармасьютиклз Гмбх	Терапевтически активные триазолы и их использование
ES2662500T3 (es) *	2006-11-21	2018-04-06	Asarina Pharma Ab	El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central
CA2698172C (en) *	2007-06-15	2014-02-18	Cook, Kevin M.	Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CZ302050B6 (cs) *	2009-08-04	2010-09-15	Ústav organické chemie a biochemie, Akademie ved CR, v.v.i.	3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
WO2013036835A1 (en)	2011-09-08	2013-03-14	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
US10478505B2 (en)	2011-09-23	2019-11-19	The Regents Of The University Of California	Edible oils to enhance delivery of orally administered steroids
CN113234114A (zh)	2011-10-14	2021-08-10	萨奇治疗股份有限公司	3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
CA2862076C (en)	2012-01-23	2020-04-21	Sage Therapeutics, Inc.	Neuroactive steroid formulations and methods of treating cns disorders
CN102702126B (zh) *	2012-04-26	2014-08-06	四川大学华西医院	一种可用于麻醉剂的化合物
PL2887944T3 (pl)	2012-08-21	2022-02-21	Sage Therapeutics, Inc.	Allopregnanolon do leczenia lekoopornego stanu padaczkowego
JP2016501876A (ja)	2012-11-30	2016-01-21	ザリージェンツオブザユニバーシティオブカリフォルニア	ステロイドの抗痙攣活性
RS67266B1 (sr)	2013-03-13	2025-10-31	Sage Therapeutics Inc	Neuroaktivni steroidi i postupci za njihovu upotrebu
MX362543B (es)	2013-04-17	2019-01-24	Sage Therapeutics Inc	Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2014169832A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
WO2014169836A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
HRP20210610T1 (hr)	2013-07-19	2021-05-28	Sage Therapeutics, Inc.	Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) *	2013-08-23	2019-01-28	Sage Therapeutics Inc	Esteroides neuroativos, composições e seus usos
SG10201803812TA (en) *	2014-05-29	2018-06-28	Sage Therapeutics Inc	Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
WO2015195967A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10172870B2 (en)	2014-09-02	2019-01-08	The Texas A&M University System	Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar)	2014-09-08	2017-06-16	Sage Therapeutics Inc	سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4275748A3 (en)	2014-10-16	2024-01-03	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
EP3885352B1 (en) *	2014-10-16	2024-11-27	Sage Therapeutics, Inc.	A compound, compositions thereof and this compound for use in methods of treating cns disorders
RS60343B1 (sr)	2014-11-27	2020-07-31	Sage Therapeutics Inc	Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it)	2015-01-26	2021-05-07	Sage Therapeutics Inc	Composizioni e metodi per trattare disturbi del snc
EP3258939B1 (en)	2015-02-20	2022-09-07	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
JP6882996B2 (ja)	2015-07-06	2021-06-02	セージセラピューティクス，インコーポレイテッド	オキシステロールおよびそれらの使用の方法
SMT202100476T1 (it)	2015-07-06	2021-09-14	Sage Therapeutics Inc	Ossisteroli e metodi di uso degli stessi
BR112018000129B1 (pt)	2015-07-06	2024-01-09	Sage Therapeutics, Inc	Compostos oxiesteróis, seus usos e composição farmacêutica
US9637514B1 (en)	2015-10-26	2017-05-02	MAX BioPharma, Inc.	Oxysterols and hedgehog signaling
CN113616661A (zh)	2016-03-08	2021-11-09	萨奇治疗股份有限公司	神经活性类固醇、其组合物及用途
SI3436022T1 (sl)	2016-04-01	2022-08-31	Sage Therapeutics, Inc.	Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en)	2016-05-06	2017-11-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
ES2884071T3 (es)	2016-07-07	2021-12-10	Sage Therapeutics Inc	24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
MA45599A (fr)	2016-07-11	2019-05-15	Sage Therapeutics Inc	Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en)	2016-07-11	2022-02-24	Sage Therapeutics, Inc.	C7, C12, and C16 substituted neuroactive steroids and their methods of use
MX392270B (es)	2016-09-30	2025-03-24	Sage Therapeutics Inc	Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EP4105223B1 (en)	2016-10-18	2025-04-30	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
CN110267966B (zh)	2016-10-18	2022-07-08	萨奇治疗股份有限公司	氧甾醇及其使用方法
TW202014192A (zh) *	2018-05-04	2020-04-16	加拿大商阿爾宙斯製藥有限公司	神經類固醇衍生物及其用途
EP4321519A3 (en) *	2018-10-12	2024-05-01	Sage Therapeutics, Inc.	Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
CN109503694A (zh) *	2018-11-21	2019-03-22	苏州闻天医药科技有限公司	一种新型gabaa受体调节剂及其用途
KR20210105934A (ko)	2018-12-17	2021-08-27	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
KR102821994B1 (ko) *	2019-01-08	2025-06-19	쳉두 캉홍 파마슈티칼 코., 엘티디.	스테로이드 화합물, 및 이의 용도와 제조방법
CN111410673A (zh) *	2019-01-08	2020-07-14	成都康弘药业集团股份有限公司	甾体类化合物、用途及其制备方法
CA3124703C (en) *	2019-01-14	2023-10-17	Beijing Xuanyi Pharmasciences Co., Ltd.	Tetrazolone substituted steroids and use thereof
AR119047A1 (es)	2019-05-31	2021-11-17	Sage Therapeutics Inc	Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
KR102890254B1 (ko)	2019-08-07	2025-11-24	상하이 한서 바이오메디컬 컴퍼니 리미티드	스테로이드 유도체 조절제의 염 및 결정형
CN112341511A (zh) *	2019-08-09	2021-02-09	南京诺瑞特医药科技有限公司	3-羟基-5-孕烷-20-酮衍生物及其用途
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2021174205A1 (en) *	2020-02-27	2021-09-02	Brii Biosciences, Inc.	Prodrugs of neuroactive steroids
EP4200312A4 (en) *	2020-08-20	2024-09-25	Intra-Cellular Therapies, Inc.	ORGANIC COMPOUNDS
WO2023060067A1 (en)	2021-10-04	2023-04-13	Marinus Pharmaceuticals, Inc.	Amorphous solid dispersion ganaxolone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274179A (en) *	1964-03-19	1966-09-20	Merck & Co Inc	3-haloethynyl-3-hydroxy derivatives of the androstane-17-one and pregnane-20-one series
US3953429A (en) *	1970-12-17	1976-04-27	Glaxo Laboratories Limited	Anaesthetic steroids of the androstance and pregnane series
GB1430942A (en) *	1972-05-05	1976-04-07	Glaxo Lab Ltd	21-substituted 3alpha-hydroxy pregnanes
US5120723A (en) *	1987-08-25	1992-06-09	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
US5232917A (en) *	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0603312A4 (en) *	1991-09-13	1995-06-07	Cocensys Inc	NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
JP4008024B2 (ja) *	1993-05-24	2007-11-14	パーデュー、ファーマ、リミテッド、パートナーシップ	Ｇａｂａａレセプター複合体と相互作用させるための化合物

1995
- 1995-02-14 DK DK00200119T patent/DK1038880T3/da active
- 1995-02-14 IL IL11263895A patent/IL112638A/xx not_active IP Right Cessation
- 1995-02-14 AT AT95913478T patent/ATE195654T1/de active
- 1995-02-14 JP JP52135695A patent/JP4066272B2/ja not_active Expired - Fee Related
- 1995-02-14 PT PT00200119T patent/PT1038880E/pt unknown
- 1995-02-14 WO PCT/US1995/001712 patent/WO1995021617A1/en not_active Ceased
- 1995-02-14 DE DE69535623T patent/DE69535623T2/de not_active Expired - Lifetime
- 1995-02-14 BR BR9506779A patent/BR9506779A/pt not_active IP Right Cessation
- 1995-02-14 AU AU20901/95A patent/AU691905B2/en not_active Ceased
- 1995-02-14 EP EP00200119A patent/EP1038880B1/en not_active Expired - Lifetime
- 1995-02-14 DK DK95913478T patent/DK0752860T3/da active
- 1995-02-14 NZ NZ282939A patent/NZ282939A/en not_active IP Right Cessation
- 1995-02-14 EP EP95913478A patent/EP0752860B1/en not_active Expired - Lifetime
- 1995-02-14 ES ES00200119T patent/ES2296594T3/es not_active Expired - Lifetime
- 1995-02-14 CA CA002183231A patent/CA2183231A1/en not_active Abandoned
- 1995-02-14 DE DE69518509T patent/DE69518509T2/de not_active Expired - Lifetime
- 1995-02-14 AT AT00200119T patent/ATE375993T1/de active
- 1995-02-14 KR KR1019960704396A patent/KR100338287B1/ko not_active Expired - Fee Related
- 1995-02-14 ES ES95913478T patent/ES2151593T3/es not_active Expired - Lifetime
- 1995-02-14 PT PT95913478T patent/PT752860E/pt unknown
1996
- 1996-08-12 NO NO963355A patent/NO308307B1/no not_active IP Right Cessation
- 1996-08-13 FI FI963174A patent/FI118008B/fi not_active IP Right Cessation
2000
- 2000-11-10 GR GR20000402497T patent/GR3034810T3/el unknown
2005
- 2005-12-09 FI FI20051271A patent/FI118687B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1038880A2 (en)	2000-09-27
DK1038880T3 (da)	2008-03-03
DE69535623D1 (de)	2007-11-29
DE69518509T2 (de)	2001-04-19
EP0752860A4 (en)	1998-05-06
PT752860E (pt)	2000-12-29
HK1014665A1 (en)	1999-09-30
IL112638A (en)	2003-10-31
NO308307B1 (no)	2000-08-28
ES2151593T3 (es)	2001-01-01
GR3034810T3 (en)	2001-02-28
PT1038880E (pt)	2008-01-29
AU2090195A (en)	1995-08-29
AU691905B2 (en)	1998-05-28
EP0752860A1 (en)	1997-01-15
CA2183231A1 (en)	1995-08-17
DK0752860T3 (da)	2000-11-13
JPH09510701A (ja)	1997-10-28
WO1995021617A1 (en)	1995-08-17
DE69535623T2 (de)	2008-07-24
KR100338287B1 (ko)	2002-11-30
FI118687B (fi)	2008-02-15
EP0752860B1 (en)	2000-08-23
NZ282939A (en)	1998-08-26
FI963174A0 (fi)	1996-08-13
BR9506779A (pt)	1997-10-14
JP4066272B2 (ja)	2008-03-26
FI118008B (fi)	2007-05-31
FI963174L (fi)	1996-09-25
NO963355D0 (no)	1996-08-12
DE69518509D1 (de)	2000-09-28
IL112638A0 (en)	1995-05-26
ATE195654T1 (de)	2000-09-15
ATE375993T1 (de)	2007-11-15
EP1038880A3 (en)	2003-07-16
NO963355L (no)	1996-10-11
ES2296594T3 (es)	2008-05-01
EP1038880B1 (en)	2007-10-17

Publication	Publication Date	Title
FI20051271L (fi)	2005-12-09	Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi
FI972202L (fi)	1997-07-17	Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
BR9509200A (pt)	1997-12-30	Composição de matéria
FI973828A0 (fi)	1997-09-29	Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
PT874558E (pt)	2004-03-31	Composicoes liquidas orais compreendendo um composto de calcio e um acidulante
FI953180L (fi)	1995-12-29	Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
FI970522L (fi)	1997-04-07	Koostumukset ja menetelmät pidennetyn paikallisanestesian aikaansaamiseksi
DE69817760D1 (de)	2003-10-09	Polymerisierbare zusammensetzung für dentalanwendungen
ATE198986T1 (de)	2001-02-15	Topische zusammensetzung enthaltend ein antagonist der substanz p
FI973518L (fi)	1997-08-27	Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
BR9601630A (pt)	1998-03-31	Uso de uma quantidade eficaz de pelo menos um composto do tipo retinóide e compostos
BR9609738A (pt)	1999-03-16	Composições para aplicação de droga para estabilidade melhorada de esteróides
DK1021194T3 (da)	2003-09-01	Ny forbedret formulering til behandling af osteoporose
DE69723398D1 (de)	2003-08-14	Polyalkylphenoxyaminoalkane und diese enthaltende freibstoffzusammensetzungen
BR9507166A (pt)	1997-09-09	Conjunto de dentes para tratamento de uma superfície
PT1014987E (pt)	2004-06-30	Composicoes orais de levosimendano
NO953961L (no)	1996-04-09	Antihypertriglyseridemisk sammensetning
FI972308A7 (fi)	1997-05-30	2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä si sältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FI971750A0 (fi)	1997-04-24	Koostumuksia multippeliskleroosia varten ja sen hoito
DE69505878D1 (de)	1998-12-17	Flüssigkristallzusammensetzungen
DE69332605D1 (de)	2003-02-06	Allosterische modulatoren des nmda-rezeptors
DE69703641D1 (de)	2001-01-11	Entwicklerzusammensetzungen
ATE209249T1 (de)	2001-12-15	Flüssigkristallzusammensetzungen
DE69524127D1 (de)	2002-01-10	Flüssigentwicklerzusammensetzung
KR970702904A (ko)	1997-06-10	중합성 조성물(polymerizable compositions)

Legal Events

Date	Code	Title	Description
2008-02-15	FG	Patent granted	Ref document number: 118687 Country of ref document: FI
2013-09-17	MM	Patent lapsed

Date

Code

Title

Description

2008-02-15

Patent granted

Ref document number: 118687

Country of ref document: FI

2013-09-17

Patent lapsed